Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AMS vs GRAL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
GRAL Captures Overall Composite Edge (54.5 HOLD vs 33.8 SELL), While AMS Leads 4–2 on Growth & Valuation Pillars
GRAL Overall Winner
6-Pillar Tally: AMS 4 – 2 GRAL
Matrix Metrics: AMS 5 – 5 GRAL
As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (54.5/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while AMS wins 4–2 across the 6-pillar growth and valuation breakdown. AMS trades at $1.07 (44.6x Forward P/E, -7.4% operating margin) versus GRAL at $105.60 (1.1x Forward P/E, -332.0% operating margin).
- Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. AMS 33.8/100 SELL) and 3.09β · 99% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile GRAL is in a Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About AMS vs GRAL
AMS
American Shared Hospital Services
$1.07
-0.93% 1D
Market Cap
$7.2M
TTM Revenue
$30M
Forward P/E
44.6x
Beta / 30D Vol
0.18β · 46% Vol
Unified Composite Score
33.8
SELL
Tech 24.0
Fund 38.0
Flow 50.0
Mom 30.0
Weinstein Technical Phase
Markdown · Sell / avoid
GRAL
Head-to-Head Winner
GRAIL, Inc. Common Stock
$105.60
-8.88% 1D
Market Cap
$5.2B
TTM Revenue
$167M
Forward P/E
1.1x
Beta / 30D Vol
3.09β · 99% Vol
Unified Composite Score
54.5
HOLD
Tech 35.0
Fund 49.0
Flow 57.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (AMS 4 – 2 GRAL)
1. Valuation Multiples
GRAL
Forward P/E
44.6x
1.1x
Trailing P/E
44.6x
1.1x
PEG Ratio
N/M
N/M
EV / Revenue
0.8x
31.6x
2. Growth & Scale
GRAL
Revenue Growth (YoY)
+19.2%
+3.7%
Earnings Growth (YoY)
-38.1%
+0.0%
TTM Revenue (USD)
$30M
$167M
Market Cap
$7.2M
$5.2B
3. Profitability & Quality
AMS
Gross Margin
34.8%
46.7%
Operating Margin
-7.4%
-332.0%
Net Profit Margin
-5.8%
-243.8%
Return on Equity (ROE)
-12.1%
-17.3%
4. Balance Sheet & Cash Flow
AMS
Cash Generation (TTM)
-$916,000
-$312M
Cash Flow Margin
-3.0%
N/A
Net Cash / Leverage
$17M Net Debt (0.95x D/E)
$57M Net Debt (0.03x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AMS
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
93.0% (53rd %ile)
Put/Call OI Skew
N/A
0.81x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
AMS
OpEx & R&D Intensity
42.2% of Rev ($13M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Care Facilities Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AMS (5) vs GRAL (5)| Institutional Metric | AMS | GRAL | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $7.2M | $5.2B | GRAL | |
| Trailing P/E Ratio | 44.6x | 1.1x | GRAL | |
| Forward P/E Ratio | 44.6x | 1.1x | GRAL | |
| Revenue Growth (YoY) | +19.2% | +3.7% | AMS | |
| Operating Margin (TTM) | -7.4% | -332.0% | AMS | |
| Net Profit Margin | -5.8% | -243.8% | AMS | |
| Return on Equity (ROE) | -12.1% | -17.3% | AMS | |
| 52-Week Range Position | 6% ($1–$2) | 51% ($42–$166) | GRAL | |
| Beta / 30D Volatility | 0.18β · 46% Vol | 3.09β · 99% Vol | AMS | |
| Unified Institutional Score | 33.8 / 100 (SELL) | 54.5 / 100 (HOLD) | GRAL | |
| Trailing 12M Revenue (USD) | $30M | $167M | Scale | |
| Gross Profit Margin (TTM) | 34.8% | 46.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.8x EV/Rev | N/M PEG · 31.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$916,000 ($17M Net Debt (0.95x D/E)) | -$312M ($57M Net Debt (0.03x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
GRAL +6.05 pp
3M Horizon
GRAL +81.93 pp
6M Horizon
GRAL +104.24 pp
1Y Horizon
GRAL +79.15 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AMS Revenue | GRAL Revenue | AMS Op. Margin | GRAL Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $20M | N/A | 9.4% | N/A | AMS |
| FY2019 | $20M | N/A | 7.5% | N/A | AMS |
| FY2020 | $20M | N/A | -53.1% | N/A | AMS |
| FY2021 | $20M | N/A | 7.7% | N/A | AMS |
| FY2022 | $20M | N/A | 12.3% | N/A | AMS |
| FY2023 | $20M | $90M | 1.3% | -1627.6% | AMS |
| FY2024 | $30M | $130M | -9.9% | -1743.0% | AMS |
| FY2025 | $30M | $150M | -12.8% | -382.0% | AMS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
AMS
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact AMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
GRAL
BREAKDOWN
Current IV
93.0%
IV Percentile
53rd %ile
Put/Call OI Skew
0.81x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
AMS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
OpEx & R&D Reinvestment
42.2% of Rev ($13M)
90D Engineering Disclosures
0 Published
Taiwan Semiconductor Manufacturing Company
GlobalFoundries
ASE Technology Holding
Amkor Technology
GRAL Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ AMS vs GRAL Key Questions & Quantitative Answers
As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (54.5/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while AMS wins 4–2 across the 6-pillar growth and valuation breakdown. AMS trades at $1.07 (44.6x Forward P/E, -7.4% operating margin) versus GRAL at $105.60 (1.1x Forward P/E, -332.0% operating margin). Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. AMS 33.8/100 SELL) and 3.09β · 99% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile GRAL is in a Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GRAL leads the Growth & Scale pillar: AMS posts +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin), compared with GRAL at +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AMS cumulative revenue shifted +50.0% while GRAL shifted +66.7%. In operating R&D and SG&A reinvestment, AMS deploys 42.2% of Rev ($13M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRAL.
GRAL screens cheaper on headline valuation multiples. AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin), whereas GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMS (-12.1% ROE) versus GRAL (-17.3% ROE) capital efficiency.
In options market volatility and institutional positioning, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk). By comparison, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
GRAL vs AMS · Reverse Pair
AMS vs BYFC
· Sector Peer
GRAL vs RVMD
· Sector Peer
GRAL vs WGS
· Sector Peer
GRAL vs NTRA
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma